(RTTNews) – Kamada Ltd. (KMDA) has signed an agreement with the Israeli Ministry of Health to supply its hyperimmunoglobulin immunoglobulin (IgG) product derived from anti-SARS-CoV-2 plasma for the treatment of patients with COVID-19 in Israel The company expects the initial offer to generate approximately $3. 4 million in profits for Kamada in the first quarter of 2021.
Treatment with Kamada’s experimental IgG product will be regulated through the Israeli Ministry of Health. Phase 1/2 testing in Israel is being conducted as a component of Kamada’s global collaboration with Kedrion Biopharma for the development, manufacture and distribution of a plasma-derived IgG product as a possible remedy for COVID-19.
Amir London, CEO, said: “We are encouraged by the provisional effects of the ongoing Phase 1/2 clinical trial in Israel, in which our product demonstrated a favorable protection profile and showed advanced symptoms in patients with vent-free hospitalized COVID-19 pneumonia. , and we will continue to boost production and product in the coming months. “